POM-V Prescription Required

Tildren 500 mg Lyophilisate for Solution for Infusion for Horses

Active ingredient: Tiludronic Acid

Form

Solution

Species

Horses

Manufacturer

AUDEVARD

VMD MA No.

44684/5003

What it's used for

As an aid in the treatment of clinical signs of lameness associated with bone spavin in combination with a controlled exercise regime.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Tiludronic Acid

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Tildren 500 mg Lyophilisate for Solution for Infusion for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

As an aid in the treatment of clinical signs of lameness associated with bone spavin
in combination with a controlled exercise regime.

Intravenous infusion after reconstitution and dilution.

Revised: June 2024
AN: 02920/2023Page 5 of 8
1 mg of tiludronic acid per kg of body weight, corresponding to 5 ml of reconstituted
solution per 100 kg.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Preparation of the ready-to-use solution for infusion:
-
ml of 0.9% Sodium Chloride solution or 5% Glucose solution from a 1 l to 3
l infusion container.
-
of powder.
-
as a clear, particle free and colourless solution.
-
immediately into the infusion container
-
-
vein and connected to the infusion container with sterile disposable
infusion tubing.
-
visible solid particles should not be administered.
The product should be infused over 30 minutes at an even rate. Fluctuations in the
infusion rate could increase the risk of the horse showing signs of colic during or after
the infusion.
Do not exceed the infusion rate as this could increase the risk of the horse showing
signs of colic during or after infusion.
Do not exceed the recommended dosage.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
In the absence of any data relating to the adverse effects of tiludronic acid on the
skeleton of young animals, do not administer to a horse less than 3 years old.

Revised: June 2024
AN: 02920/2023Page 2 of 8
Do not administer to horses with impaired renal function. Renal function should
ideally be evaluated prior to treatment.
Do not use in pregnant or lactating mares (see section 3.7).
Do not use in horses producing milk for human consumption (see also section 3.12).

Horse:
Common
(1 to 10 animals / 100 animals
treated):
Colic
Discomfort
(belly watching, yawning, pawing or
kicking, stretching, light bruxism)
Restlessness
Increased sweating
Soft stool
Rare
(1 to 10 animals / 10,000
animals treated):
Acute renal failure
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction
Anaphylaxis
Undetermined frequency
(cannot be estimated from the
available data):
Recumbency
1
Signs of colic appear within a few hours following treatment, are mild and generally
resolve without any specific treatment. In case signs persist, conventional treatments
should be administered. The administration of an alpha 2 adrenergic agonist prior
infusion may reduce the occurrence of signs of colic.
An increase in frequency of signs of discomfort and restlessness is observed when
the infusion duration is less than 15 minutes.

Revised: June 2024
AN: 02920/2023Page 4 of 8
may occur within 1 week after administration. Renal parameters should be
monitored before administration and water consumption and urine output should be
monitored where possible after administration. Renal insufficiency is more frequently
observed in animals concurrently exposed to NSAIDs. In these cases, appropriate
fluid therapy should be instituted, and renal parameters monitored.
signs of reaction ranged from urticaria to anaphylactic shock, which can be fatal. A
ppropriate treatment should be sought immediately.
may occur after the infusion. Care should be taken to ensure that the horse can lie
down in a comfortable, unrestricted area.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
The clinical effect of the veterinary medicinal product depends on the presence of
osteolytic processes causing pain and leading to lameness. The product should be
used only after a proper diagnosis combining a complete orthopaedic clinical
examination including local analgesia and appropriate imaging techniques in order to
identify the cause of pain and the nature of bone lesions.
It is recommended to respect the recommended 30 minute duration of infusion as the
duration of infusion has an effect on the occurrence or severity of the adverse
reactions.
It is advisable for an experienced horse person to observe the horse for the first four
hours following the infusion due to the possible onset of side effects.
The product should be administered with caution in a hypocalcemic horse. In this
case, it is advised to slow down the speed of the infusion. As the risk of side effects
might be increased under these circumstances, these animals should be the subject
of particularly close surveillance.
Because of its mild hypocalcemic effect, the product should be administered with
caution in horses with disorders of heart function. In this case, it is advisable to slow
down the speed of infusion.
Adequate access to drinking water should be provided when using the product. If
uncertainty exists about renal function, renal parameters should be assessed before
administration of the product. Water consumption and urine output should be
monitored after administration.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Avoid contact with skin and eyes.
Avoid accidental self-injection: it is recommended to insert the intravenous infusion
needle into the vein before the reservoir containing the product is connected.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.

Revised: June 2024
AN: 02920/2023Page 3 of 8
Wear impervious gloves when preparing the solution for injection.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

Do not mix or concomitantly administer intravenously the reconstituted solution with
solutions containing divalent metal ions (Ca2+ or Mg2+) such as Lactated Ringers. A
solution of tiludronic acid may form complexes with these ions.
Avoid concomitant intravenous administration with drugs that can reduce serum
calcium (such as tetracyclines) or whose toxicity can be exacerbated by a reduction
in serum calcium (such as aminoglycosides).
Concurrent administration of potentially nephrotoxic substances, such as NSAIDs,
should be approached with caution and renal function should be monitored.
No information is available on the safety and efficacy of this veterinary medicinal
product when used with any other veterinary medicinal product.

Keep the vial in the outer carton in order to protect from light.

Meat and offal: zero days

Revised: June 2024
AN: 02920/2023Page 6 of 8
Not authorised for use in animals producing milk for human consumption.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.